Avadel Pharmaceuticals PLC
NASDAQ:AVDL

Watchlist Manager
Avadel Pharmaceuticals PLC Logo
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Watchlist
Price: 10.61 USD 3.71% Market Closed
Market Cap: 1B USD
Have any thoughts about
Avadel Pharmaceuticals PLC?
Write Note

Avadel Pharmaceuticals PLC
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Avadel Pharmaceuticals PLC
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Cash & Cash Equivalents
$28.6m
CAGR 3-Years
-21%
CAGR 5-Years
17%
CAGR 10-Years
2%
Perrigo Company PLC
NYSE:PRGO
Cash & Cash Equivalents
$1.5B
CAGR 3-Years
-11%
CAGR 5-Years
30%
CAGR 10-Years
5%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Cash & Cash Equivalents
$2.2B
CAGR 3-Years
60%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Cosmo Pharmaceuticals NV
SIX:COPN
Cash & Cash Equivalents
€54.6m
CAGR 3-Years
-33%
CAGR 5-Years
-19%
CAGR 10-Years
7%
Ovoca Bio PLC
LSE:OVB
Cash & Cash Equivalents
€2.9m
CAGR 3-Years
-32%
CAGR 5-Years
2%
CAGR 10-Years
-11%
No Stocks Found

Avadel Pharmaceuticals PLC
Glance View

Market Cap
1B USD
Industry
Pharmaceuticals
Economic Moat
None

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.

AVDL Intrinsic Value
17.97 USD
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Avadel Pharmaceuticals PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
28.6m USD

Based on the financial report for Sep 30, 2024, Avadel Pharmaceuticals PLC's Cash & Cash Equivalents amounts to 28.6m USD.

What is Avadel Pharmaceuticals PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
2%

Over the last year, the Cash & Cash Equivalents growth was -45%. The average annual Cash & Cash Equivalents growth rates for Avadel Pharmaceuticals PLC have been -21% over the past three years , 17% over the past five years , and 2% over the past ten years .

Back to Top